Neurocritical Care News

Prilenia Therapeutics announced the completion of its global phase 3 study of pridopidine for Huntington’s disease, with topline results expected in the next few months.

Steroid use for at least 10 days before surgery was significantly associated with infectious and noninfectious complications, hospital readmissions and mortality in patients undergoing craniotomy for brain tumors, according to research.

Neuraly has announced that its investigational NLY01 did not meet the primary study endpoint of improvement in motor symptoms in patients with early, untreated Parkinson’s disease.

Delandistrogene moxeparvovec improved motor function and was well-tolerated 4 years after treatment in a small cohort of children with Duchenne muscular dystrophy, according to a poster at the 2023 MDA Clinical & Scientific Conference.

Treatment with givinostat was associated with improvement in mobility and physical function compared with placebo in ambulant boys with Duchenne muscular dystrophy, according to a poster at the 2023 MDA Clinical & Scientific Conference.

Eterna Therapeutics Inc. announced it has entered into an exclusive option and license agreement with Lineage Cell Therapeutics Inc. to create novel induced hypoimmune pluripotent stem cell lines for use in cell transplant therapies.

Horizon Therapeutics recently announced new MRI imaging data from a phase 3 clinical trial, which demonstrated that Uplizna reduced formation of asymptomatic optic nerve lesions in patients with neuromyelitis optica spectrum disorder.

Men aged 65 years and older had a significantly higher rate of skull fracture compared with women after blunt head trauma, mostly because of falls, according to a study from The American Journal of Emergency Medicine.

The emergence of visual artistic creativity among those with frontotemporal dementia may be linked to early lesion-induced activation of the visual cortex and may depend on environment or genetics, according to research presented in JAMA Neurology.

Sintalica Bioscience Corp. announced it has cultivated, harvested and processed its first batch of psilocybin mushrooms and has synthesized psychedelic molecules with enhanced anti-inflammatory properties and no hallucinogenic effects.